Sharing Data to Accelerate Medicines Development and Improve Neonatal Care: Data Standards and Harmonized Definitions
October 11, 2018 Comparability of a Provisioned Device Versus Bring Your Own Device for Completion of Patient-Reported Outcome (PRO) Measures by Participants with Chronic Obstructive Pulmonary Disease (COPD): Quantitative Interview Findings
Profiles in Business with Tucson Metro Chamber C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact a
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme
November 3, 2018 D-RSC and PSTC presented “Biomarkers for Muscle Diseases” poster at the 2018 MDA Clinical Conference
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s Disease TUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC),
FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration Major Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials. October 25, 2018 —
New Frontiers in Parkinson’s Disease: From Genetics to the Clinic Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP. New Frontiers in Parkinson’s Disease: From Genetics to the
UA Colleges of Law and Pharmacy, Critical Path Institute, Launch Graduate Certificate Program in Regulatory Science Designed for graduate students and working professionals, the certificate program provides specialized training in navigating the